Symptoms Associated with Chemotherapy-Induced Peripheral Neuropathy

Last updated: February 17, 2025
Sponsor: Izmir Bakircay University
Overall Status: Completed

Phase

N/A

Condition

Breast Cancer

Cancer

Neurologic Disorders

Treatment

European Organization for Research and Treatment of Cancer-Chemotherapy Induced Peripheral Neuropathy (EORTC-CIPN20) questionnaire

Clinical Study ID

NCT06352567
BakircayU1394/1414
  • Ages 18-80
  • Female

Study Summary

Breast cancer remains the most frequent type of cancer globally. Nevertheless, the increased rate of disease-free survival of breast cancer brought the specific need of managing of short and long-term side effects of multimodal treatment. Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most debilitating conditions which is characterized by a wide variety of experienceable symptoms by patients that need to be addressed in detail. Therefore, in this cross-sectional study, it was aimed to assess the potential symptoms associated with CIPN of patients with breast cancer who underwent systemic chemotherapy. In addition, it was aimed to assess the potential associations between experienced symptoms of CIPN and sociodemographic (age, body mass index etc.) and clinical features (mean exposed dose, type of surgery (if any) etc.).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Being a volunteer to participate

  • aged over 18 years old

  • being female

  • being a candidate for systemic chemotherapy

Exclusion

Exclusion Criteria:

  • Having distant metastasis

  • Having comorbidities that might contribute to or cause sensorial and motor deficitssuch as multiple sclerosis, diabetes, polyneuropathy, etc.,

  • Prolonged surgical (if any) complications (i.e. pain, seroma, etc.)

Study Design

Total Participants: 74
Treatment Group(s): 1
Primary Treatment: European Organization for Research and Treatment of Cancer-Chemotherapy Induced Peripheral Neuropathy (EORTC-CIPN20) questionnaire
Phase:
Study Start date:
January 18, 2024
Estimated Completion Date:
August 15, 2024

Study Description

Patients with breast cancer who underwent systemic chemotherapy were assessed with the European Organization for Research and Treatment of Cancer-Chemotherapy Induced Peripheral Neuropathy (EORTC-CIPN20) questionnaire within 1-2 months after completion of systemic chemotherapy. A simple data form was implemented in which patients' age, weight, height, marital status, smoking status, etc were investigated. In addition, the dose of the exposure of systemic chemotherapy was calculated according to the Body Surface Area (BSA) and DuBois formulation as follows: BSA [m2] = Weight [kg]0.425 × height (cm)0.725 × 0.007184]. The universal dose calculations were used to calculate the mean exposure according to the following doses for each patient-specific to their chemotherapy regimen: Four cycles of Anthracycline were applied 14 days apart 60 mg/m2 intravenous (IV), 12 cycles of Paclitaxel were applied seven days apart 80 mg/m2 IV, and four cycles of Docetaxel were applied 21 days apart 75 mg/m2 IV.

Connect with a study center

  • Bakircay University Çiğli State and Training Hospital, Department of Medical Oncology

    İzmir, Çiğli 35620
    Turkey

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.